drugset / Trial / NCT04686591

Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

NCT04686591

Phase 1 Completed 8 enrolled AstraZeneca Quotient Sciences · collab
Non-randomizedCrossoverOpen-labelBasic science

Summary

Study to Assess the Absorption, Metabolism, and Excretion of \[14C\]AZD9977 after a Single-Dose Oral Administration

Timeline

Start
2020-12-21
Primary completion
2021-02-04
Completion
2021-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject balcinrenone Small molecule 100 ug Oral
Subject balcinrenone Small molecule 100 mg Oral